These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 26278156)

  • 21. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers.
    Coutant C; Rouzier R; Qi Y; Lehmann-Che J; Bianchini G; Iwamoto T; Hortobagyi GN; Symmans WF; Uzan S; Andre F; de Thé H; Pusztai L
    Clin Cancer Res; 2011 Apr; 17(8):2591-601. PubMed ID: 21248301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A six-gene signature predicting breast cancer lung metastasis.
    Landemaine T; Jackson A; Bellahcène A; Rucci N; Sin S; Abad BM; Sierra A; Boudinet A; Guinebretière JM; Ricevuto E; Noguès C; Briffod M; Bièche I; Cherel P; Garcia T; Castronovo V; Teti A; Lidereau R; Driouch K
    Cancer Res; 2008 Aug; 68(15):6092-9. PubMed ID: 18676831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prognostic 4-gene expression signature for patients with HER2-negative breast cancer receiving taxane and anthracycline-based chemotherapy.
    Cheng P; Wang Z; Hu G; Huang Q; Han M; Huang J
    Oncotarget; 2017 Nov; 8(61):103327-103339. PubMed ID: 29262565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
    Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
    Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [70-Gene signature as an aid to treatment decisions in early-stage breast cancer].
    van der Hoeven JJ
    Ned Tijdschr Geneeskd; 2017; 161():D1369. PubMed ID: 28401821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A thirty-three gene-based signature predicts lymph node metastasis and prognosis in patients with gastric cancer.
    Xiao J; Wang G; Zhu C; Liu K; Wang Y; Shen K; Fan H; Ma X; Xu Z; Yang L
    Heliyon; 2023 Jun; 9(6):e17017. PubMed ID: 37484383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How Different Are the Molecular Mechanisms of Nodal and Distant Metastasis in Luminal A Breast Cancer?
    Lapcik P; Pospisilova A; Janacova L; Grell P; Fabian P; Bouchal P
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32947901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
    Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
    BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prognostic molecular classification of breast cancers based on gene expression profiling].
    Feng YM; Li XQ; Sun BC; Gao XC; Gu L; Niu Y; Hao XS
    Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):900-6. PubMed ID: 17533740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.
    Zhang Y; Sieuwerts AM; McGreevy M; Casey G; Cufer T; Paradiso A; Harbeck N; Span PN; Hicks DG; Crowe J; Tubbs RR; Budd GT; Lyons J; Sweep FC; Schmitt M; Schittulli F; Golouh R; Talantov D; Wang Y; Foekens JA
    Breast Cancer Res Treat; 2009 Jul; 116(2):303-9. PubMed ID: 18821012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Prognostic Factors for Distant Metastases in Premenopausal Patients with HR+/HER2- Early Breast Cancer.
    Ni H; Kumbrink J; Mayr D; Seiler A; Hagemann F; Degenhardt T; Sagebiel S; Würstlein R; Kates R; Harbeck N; Eggersmann TK
    J Pers Med; 2021 Aug; 11(9):. PubMed ID: 34575612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics.
    Sotgia F; Fiorillo M; Lisanti MP
    Oncotarget; 2017 Sep; 8(40):68730-68745. PubMed ID: 28978152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of prognostic gene expression signatures for breast cancer.
    Haibe-Kains B; Desmedt C; Piette F; Buyse M; Cardoso F; Van't Veer L; Piccart M; Bontempi G; Sotiriou C
    BMC Genomics; 2008 Aug; 9():394. PubMed ID: 18717985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer.
    Miller PC; Clarke J; Koru-Sengul T; Brinkman J; El-Ashry D
    Clin Cancer Res; 2015 Jan; 21(2):373-85. PubMed ID: 25370469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population-based molecular prognosis of breast cancer by transcriptional profiling.
    Ma Y; Qian Y; Wei L; Abraham J; Shi X; Castranova V; Harner EJ; Flynn DC; Guo L
    Clin Cancer Res; 2007 Apr; 13(7):2014-22. PubMed ID: 17404081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular signatures of lymph node status by intrinsic subtype: gene expression analysis of primary breast tumors from patients with and without metastatic lymph nodes.
    Shriver CD; Hueman MT; Ellsworth RE
    J Exp Clin Cancer Res; 2014 Dec; 33(1):116. PubMed ID: 25551369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
    Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
    Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epsin Family Member 3 and Ribosome-Related Genes Are Associated with Late Metastasis in Estrogen Receptor-Positive Breast Cancer and Long-Term Survival in Non-Small Cell Lung Cancer Using a Genome-Wide Identification and Validation Strategy.
    Hellwig B; Madjar K; Edlund K; Marchan R; Cadenas C; Heimes AS; Almstedt K; Lebrecht A; Sicking I; Battista MJ; Micke P; Schmidt M; Hengstler JG; Rahnenführer J
    PLoS One; 2016; 11(12):e0167585. PubMed ID: 27926932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer.
    Schmidt M; Petry IB; Böhm D; Lebrecht A; von Törne C; Gebhard S; Gerhold-Ay A; Cotarelo C; Battista M; Schormann W; Freis E; Selinski S; Ickstadt K; Rahnenführer J; Sebastian M; Schuler M; Koelbl H; Gehrmann M; Hengstler JG
    Breast Cancer Res Treat; 2011 Feb; 125(3):637-46. PubMed ID: 20352488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A robust prognostic signature for hormone-positive node-negative breast cancer.
    Griffith OL; Pepin F; Enache OM; Heiser LM; Collisson EA; Spellman PT; Gray JW
    Genome Med; 2013; 5(10):92. PubMed ID: 24112773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.